Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Forte Biosciences, Inc.NASDAQ: FBRX
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $1.97M fell 42.6% year over year, behind the -28.8% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 30.5% from the prior quarter. Over 3 fiscal years it compounded at +14.3% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -19.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.97M-30.5% QoQ
- Last fiscal yearDec 2025
- $12.41M-19.3% YoY
- LTMMar 2026
- $10.95M-28.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -42.6% | -100.0% | -57.4 pp |
| 1 year | -19.3% | -100.0% | -80.7 pp |
| 3-year CAGR | +14.3% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 12.41M USD
- Year-over-year change
- -19.3%
- 4-year CAGR
- +12.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.41M | -19.3% |
| FY2024 | 2024-12-31 | 15.37M | +44.8% |
| FY2023 | 2023-12-31 | 10.62M | +27.9% |
| FY2022 | 2022-12-31 | 8.3M | +8.8% |
| FY2021 | 2021-12-31 | 7.63M | — |
Selling, General & Admin vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -28.8% is the 9th highest of 10, against a peer median of -3.8%.
- Over three fiscal years its annual growth of +14.3% compares with a peer median of +2.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.37M USD | -20.9% | -4.0% | 257.2% | |
| LTM Mar 2026 | $42.34M USD | -49.3% | -18.0% | 670.4% | |
| LTM Mar 2026 | $25.06M USD | -19.7% | +4.0% | — | |
| LTM Mar 2026 | $22.56M USD | +1.9% | +16.6% | — | |
| LTM Mar 2026 | CHF 16.11M CHF | -3.8% | -12.0% | — | |
| LTM Mar 2026 | $15.52M USD | -5.5% | -6.6% | — | |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | $13.7M USD | +20.3% | +31.5% | — |
| LTM Mar 2026 | $13.02M USD | +27.1% | +2.6% | 2479.6% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $12.2M USD | +39.9% | +47.3% | — |
| LTM Mar 2026 | $10.95M USD | -28.8% | +14.3% | — | |
| Peer median (excluding FBRX) | — | -3.8% | +2.6% | 670.4% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 36K | 0 | 9K | 39K | 64K |
| Gross Profit | (36K) | 0 | (9K) | (39K) | (64K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.85M | 5.59M | 21.86M | 21.19M | 58.25M |
| Selling, General & Admin | 7.63M | 8.3M | 10.62M | 15.37M | 12.41M |
| Operating Expenses | 21.49M | 13.9M | 32.48M | 36.56M | 70.66M |
| Depreciation & Amortization | 36K | 36K | 9K | 39K | 64K |
| EBITDA | (21.67M) | (13.84M) | (31.47M) | (35.44M) | (68.27M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (21.49M) | (13.9M) | (32.49M) | (36.6M) | (70.66M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 1.12M | 1.31M | 2.72M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (222K) | 17K | 1.01M | 1.12M | 2.32M |
| Income Before Tax | (21.71M) | (13.88M) | (31.48M) | (35.48M) | (68.34M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.04M |
| Net Income | (21.71M) | (13.86M) | (31.48M) | (35.48M) | (69.38M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (38.85) | (19.96) | (24.92) | (12.17) | (4.71) |
| EPS (Diluted) | (38.85) | (19.96) | (24.92) | (12.17) | (4.71) |
| Weighted Avg Shares | 558.71K | 695.34K | 1.26M | 2.92M | 147.18M |
| Weighted Avg Shares (Diluted) | 558.71K | 695.34K | 1.26M | 2.92M | 147.18M |
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.